Cheng CH, Hao WR, Cheng TH. Advancing treatment strategies: Insights from network meta-analysis of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 99083 [DOI: 10.4251/wjgo.v17.i1.99083]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 99083 Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.99083
Advancing treatment strategies: Insights from network meta-analysis of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan
Co-first authors: Chun-Han Cheng and Wen-Rui Hao.
Author contributions: Cheng CH and Hao WR contribute equally to this study as co-first authors. Cheng CH and Hao WR wrote the paper; Cheng TH revised the paper; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: July 13, 2024 Revised: September 26, 2024 Accepted: October 23, 2024 Published online: January 15, 2025 Processing time: 152 Days and 2.4 Hours
Abstract
This study examines the pivotal findings of the network meta-analysis of Zhou et al, which evaluated the efficacy of hepatic arterial infusion chemotherapy and combination therapies for advanced hepatocellular carcinoma (HCC). This meta-analysis suggests that therapeutic combinations have greater efficacy than do standard treatments. The article highlights the key insights that have the potential to shift current clinical practice and enhance outcomes for patients with advanced HCC. Additionally, this article discusses further research that can be conducted to optimize these treatments and achieve personalized care for patients with HCC.
Core Tip: This study discusses the comprehensive findings of the network meta-analysis of Zhou et al on hepatic arterial infusion chemotherapy (HAIC) and its combination strategies for advanced hepatocellular carcinoma. It highlights the efficacy and comparative benefits of HAIC in improving treatment outcomes and emphasizes its potential as a targeted therapeutic option in clinical practice.
